The study will test a medication called cemiplimab (also known as LIBTAYO), which is given through an intravenous infusion. This medicine belongs to a group of drugs called immunotherapy, which helps the body’s immune system fight cancer cells. The purpose is to determine if giving cemiplimab after surgery can help prevent the cancer from returning, compared to patients who receive no additional treatment after surgery.

During the study, participants will either receive cemiplimab treatment or be observed without treatment. The medication will be given through an infusion into a vein every few weeks. The total treatment period may last up to 42 weeks. Doctors will monitor the participants’ health and check if the cancer returns during and after the treatment period.

The purpose of this study is to determine how effective the combination of these medications is at eliminating cancer cells before surgery. The treatment is given in two phases – before surgery (called neoadjuvant treatment) and after surgery (called adjuvant treatment). Before surgery, patients receive both medications. After surgery, all patients receive zimberelimab, and some patients may also continue receiving sacituzumab govitecan.

During the study, patients will receive regular medical examinations and various tests to monitor their health and how well the treatment is working. The treatment period may last up to 54 weeks. Zimberelimab is given at doses up to 360 milligrams, while sacituzumab govitecan is given based on the patient’s body weight, up to 10 milligrams per kilogram of body weight.

The study is divided into two parts to determine the best way to use these medicines. In the first part, different amounts of the drugs are given to find the safest and most effective dose. The second part focuses on finding the optimal dose and observing how well the combination works for different types of lung cancer. Throughout the process, the safety and how the body processes the drugs are closely monitored.

The study is divided into different parts. The first part will test different dose levels of the investigational medications to find the most suitable dose for further testing. During this phase, doctors will carefully monitor participants for any side effects. The following parts of the study will test the chosen dose in larger groups of people with advanced non-small cell lung cancer to better understand how well the treatment works and how safe it is. Throughout the study, participants will receive the medications through infusion into a vein. Doctors will regularly check how the cancer responds to treatment using imaging scans and other assessments.

During the study, participants will need to provide a tissue sample from their tumor, either from a previously stored sample or from a new biopsy if needed. The study will track various aspects of participant health and treatment response, including any side effects that occur, whether the cancer shrinks or stops growing, and how long any positive effects last. Blood samples will be collected at different times to measure the levels of the investigational medications in the body and to check whether the immune system develops a response to these medications.

The purpose of this study is to compare how well MK-2870 combined with pembrolizumab works compared to pembrolizumab alone in preventing the cancer from coming back after surgery. Before being assigned to one of these treatment groups, participants will first receive pembrolizumab along with platinum-based chemotherapy before surgery, which is called neoadjuvant treatment. After surgery, if cancer cells are still found in the removed tissue, meaning a complete response was not achieved, participants will then be randomly assigned to receive either MK-2870 plus pembrolizumab or pembrolizumab alone as adjuvant treatment, which means treatment given after surgery to reduce the risk of cancer returning.

During the study, participants will have regular check-ups that include imaging scans such as computed tomography or magnetic resonance imaging to monitor for any signs of cancer returning. The study will measure how long participants remain free of disease, how long they survive overall, and whether the cancer spreads to distant parts of the body. Researchers will also assess quality of life and monitor for any side effects throughout the treatment period. The treatment period can last up to several months, and participants will continue to be followed for a number of years to track long-term outcomes.

The purpose of the study is to evaluate the safety and effectiveness of BNT327 when used with chemotherapy. The trial is divided into two phases: Phase II and Phase III. In Phase II, the focus is on assessing how safe and tolerable BNT327 is at different dose levels when combined with chemotherapy. In Phase III, the study will compare the effectiveness of BNT327 combined with chemotherapy to the combination of pembrolizumab and chemotherapy. The study will also look at how these treatments affect the progression of the disease and overall survival of participants.

Participants in the study will receive treatment over a period of time, with regular follow-up visits to monitor their health and the effects of the treatment. The study aims to provide valuable information on the potential benefits and risks of using BNT327 in treating non-small cell lung cancer, which could lead to new treatment options for patients in the future.

The purpose of the study is to see if using Pembrolizumab as a maintenance therapy after patients have received a combination of chemotherapy and radiation therapy can help improve their overall survival. The study will compare two groups of patients: one group will receive Pembrolizumab for up to 24 months, while the other group will be observed without additional treatment after their initial therapy. This will help researchers understand if Pembrolizumab can provide better outcomes for patients with this type of lung cancer.

Participants in the study will first undergo chemotherapy and radiation therapy. After this initial treatment, they will either receive Pembrolizumab or be placed under observation. The study will monitor the patients over time to assess their overall survival and how long they remain free from cancer progression. The goal is to determine if Pembrolizumab can extend the lives of patients with stage III NSCLC compared to those who do not receive the maintenance therapy.

The purpose of this research is to determine how effective a combined treatment approach is for patients with this type of lung cancer. The treatment plan includes initial therapy with immunotherapy and chemotherapy, followed by either surgery or a combination of chemotherapy and radiation therapy. After these treatments, patients receive additional immunotherapy for up to 12 months.

During the study, patients will receive medications through infusion, which means the drugs are given directly into a vein. Doctors will monitor how well the treatment works and track any side effects that may occur. The study will measure how long patients live without their cancer getting worse or returning after treatment begins.

The purpose of the study is to evaluate the safety and effectiveness of combining Durvalumab with two different types of radiation therapy. One type is the conventional method, and the other is an optimized method called hypofractionated radiotherapy, which involves giving larger doses of radiation over a shorter period. The study aims to see how well these treatments work together in improving the response rates in patients with this type of lung cancer.

Participants in the study will receive either the conventional or the hypofractionated radiation therapy along with Durvalumab. The study will monitor the safety of these treatments and how well they are tolerated by the patients. It will also look at how the cancer responds to the treatment over time. The study is expected to last for a period of up to 12 months, during which patients will have regular hospital visits for treatment and follow-up examinations.

Participants in the study will receive treatments through an intravenous infusion, which means the medication is given directly into a vein. The medications used in the study include cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, which are all types of chemotherapy drugs. These drugs work by targeting and killing cancer cells. The study will also use durvalumab, an immunotherapy drug that helps the immune system recognize and attack cancer cells.

The study will take place over a period of time, with participants receiving treatment for up to 16 weeks. The goal is to determine if adding durvalumab after the initial treatment can help prevent the cancer from returning. Participants will be monitored throughout the study to assess their response to the treatment and any side effects they may experience. The study is designed to provide valuable information on improving treatment outcomes for patients with early-stage NSCLC.

The purpose of the study is to evaluate the effectiveness and safety of these treatments when given before and after surgery. The study will follow a course where patients receive the treatments before surgery to shrink the tumor, known as neoadjuvant treatment, and then continue with additional treatments after surgery, known as adjuvant treatment. The study aims to see how well these treatments work in reducing the cancer and how safe they are for patients.

Participants in the study will receive either the active medications or a placebo. The study will monitor the response of the cancer to the treatments, as well as any side effects experienced by the participants. The goal is to gather information that could help improve treatment options for patients with early-stage NSCLC that can be surgically removed.

Participants in the study will be randomly assigned to one of two groups. One group will receive Ociperlimab in combination with Tislelizumab, while the other group will receive Pembrolizumab followed by a placebo. The treatments are given as infusions, which means they are administered directly into the bloodstream through a vein. The study will monitor the participants over a period of time to assess the effectiveness of the treatments in improving survival rates.

The trial aims to provide valuable information on how these treatments can help patients with non-small cell lung cancer. By comparing the different treatment options, researchers hope to find the most effective approach for managing this type of cancer. The study will also look at the quality of life of participants and any side effects they may experience during the trial.

The main goal of the study is to assess the safety and how well patients tolerate ATL001 as a treatment. Participants in the study will receive the treatment through an infusion, which means the medication is given directly into the bloodstream. The study will monitor patients over time to see how their cancer responds to the treatment and to check for any side effects. The study will also compare the effects of the treatment with those of a placebo.

Throughout the study, patients will have regular check-ups to track their health and the progress of their cancer. The study will measure changes in tumor size and overall health outcomes, such as how long patients live without their cancer getting worse. This research aims to provide new insights into treating non-small cell lung cancer and potentially offer new options for patients with this type of cancer.

The purpose of the study is to explore the possibility of performing surgery after patients have received high-dose chemotherapy and radiation therapy, which is a combination treatment often referred to as chemoradiotherapy. After surgery, the study will also look at whether patients can continue with Durvalumab as a follow-up treatment, known as consolidation therapy. This approach aims to see if adding surgery and Durvalumab can be a feasible treatment plan for patients with Stage III NSCLC.

Participants in the study will first undergo chemoradiotherapy. If surgery is deemed possible, it will be performed within 12 weeks after completing the chemoradiotherapy. Following surgery, patients will receive Durvalumab to help consolidate the treatment. The study will monitor the ability to perform surgery and the continuation of Durvalumab treatment, as well as any side effects or complications that may arise during the process.

Participants in the study will receive treatment with amivantamab for four weeks. In the first stage, amivantamab will be given by itself. In the second stage, it will be combined with carboplatin and pemetrexed disodium. After the treatment, patients will undergo surgery to remove the cancer. If needed, additional treatments such as chemotherapy, radiation therapy, or medications targeting EGFR mutations may be provided after surgery.

The study aims to determine if this approach is feasible and safe for patients with early-stage or locally advanced non-small-cell lung cancer that can be surgically removed. The study will also look at how the cancer responds to the treatment and how it affects the patient’s health and recovery after surgery.

The purpose of the study is to determine how well osimertinib works in keeping the cancer from coming back, which is referred to as disease-free survival. Participants in the study will be randomly assigned to receive either osimertinib or a placebo. The study will be conducted in a way that neither the participants nor the researchers know who is receiving the actual medication or the placebo, a method known as double-blind. This helps ensure that the results are not influenced by expectations about the treatment.

Throughout the study, participants will be monitored for several years to assess the long-term effects of the treatment. This includes regular check-ups and tests to track their health and any changes in their condition. The study will also look at overall survival rates and the quality of life of the participants, using questionnaires and other assessments. The safety of the treatment will be closely watched by checking for any side effects or health changes during the study period.

Participants in the study will take INCB099280 in the form of a film-coated tablet. The study will test different doses of the medication, specifically 400 mg, 600 mg, and 800 mg, taken twice a day. The treatment period can last up to 24 weeks. During the study, participants will be monitored for any side effects and changes in their condition. Some participants may receive a placebo, which is a tablet that looks like the treatment but does not contain the active medication.

The study aims to gather information on how the treatment affects the tumors, including whether it can shrink them or stop them from growing. It will also look at how long any positive effects last and how the treatment impacts the overall health and survival of the participants. The results will help determine if INCB099280 could be a useful treatment option for people with these types of cancer in the future.